High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, Sao Paulo, Brazil

Imagem de Miniatura
Arquivos
art_LEVI_HighRisk_HPV_Testing_in_Primary_Screening_for_Cervical_2019.PDF (267.04 KB)
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2019
Editora
AMER ASSOC CANCER RESEARCH
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
COHEN, Diane Dede
CURY, Use
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CANCER PREVENTION RESEARCH, v.12, n.8, p.539-546, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Every year there are approximately 16,000 new cases of cervical cancer in Brazil. Novel screening technologies may reduce this number by expanding the population coverage but also by improving the detection rate of precursor lesions. We aimed to evaluate human papillomaviruses (HPV)-DNA testing in the context of routine cervical cancer screening in the public health system of the city of Sao Paulo, Brazil. Women participating in the primary screening program were invited to enroll. Liquid-based cytology samples were collected and cytology and Hr-HPV DNA testing were performed in parallel. Cytologists were blind to I IPV results. Women older than 24 years with a positive high-risk HPV test and/or cytology class >= ASC-US were referred to colposcopy. From December 2014 to December 2016, 16,102 women joined the study. High-risk human papillomavirus (HR HPV) DNA prevalence was 14.9%, whereas cytologic abnormalities were found in 7,2% of the women. Per protocol, 1,592 Hr-HPV+ women, in addition to 72 patients with cytologic classification > low-grade squamous intraepithelial lesion (LSIL) were referred. A total of 80 cervical intraepithelial neoplasia (CIN2(+)) cases were diagnosed, 79 were Hr-HPV DNA(+) and 18 had normal cytology. Hr-HPV DNA detected a significant number of patients with premalignant lesions missed by cytology and all 16 CIN3(+) cases were Hr-HPV DNA(+). HPV genotyping may be useful in the management of Hr-HPV+ women, reducing the burden of colposcopic referral for those harboring genotypes with a weaker association to CIN3(+). Use of HPV-DNA testing was shown to be feasible and advantageous over current cytologic screening in the public health system.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/33670
Referências
  1. Costa RFA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138945
  2. Arbyn M, 2015, CLIN MICROBIOL INFEC, V21, P817, DOI 10.1016/j.cmi.2015.04.015
  3. Silva GAE, 2010, CAD SAUDE PUBLICA, V26, P2398
  4. Cuschieri K, 2018, INT J CANCER, V143, P735, DOI 10.1002/ijc.31261
  5. Diaz RS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139677
  6. Ejegod D, 2016, J CLIN MICROBIOL, V54, P2267, DOI 10.1128/JCM.00508-16
  7. Flores YN, 2011, CANCER CAUSE CONTROL, V22, P261, DOI 10.1007/s10552-010-9694-3
  8. Forman D, 2013, CANC INCIDENCE 5 CON
  9. Gultekin M, 2018, INT J CANCER, V142, P1952, DOI 10.1002/ijc.31212
  10. Instituto Nacional de Cancer (Brasil), 2011, COORD GER AC ESTR
  11. Instituto Nacional de Cancer Jose Alencar Gomes da Silva, 2016, COORDENACAO DE PREVE
  12. Jeronimo J, 2016, J CLIN VIROL, V76, pS69, DOI 10.1016/j.jcv.2015.11.035
  13. Kurman R, 2014, WHO CLASSIFICATION T
  14. Lew JB, 2017, LANCET PUBLIC HEALTH, V2, pE96, DOI 10.1016/S2468-2667(17)30007-5
  15. Longatto A, 2015, ACTA CYTOL, V59, P273, DOI 10.1159/000435801
  16. Martins TR, 2018, AM J CLIN PATHOL, V149, P316, DOI [10.1093/ajcp/aqx163, 10.1093/AJCP/AQX163]
  17. Nayar R, 2015, CANCER CYTOPATHOL, V123, P271, DOI 10.1002/cncy.21521
  18. Rocha D, 2018, TRANSFUSION, V58, P862, DOI 10.1111/trf.14478
  19. Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7
  20. Schiffman M, 2011, CANCER EPIDEM BIOMAR, V20, P1398, DOI 10.1158/1055-9965.EPI-11-0206
  21. Smelov V, 2015, INT J CANCER, V136, P1171, DOI 10.1002/ijc.29085
  22. Speck NMG, 2018, DOSSIE ESTRATEGIAS R
  23. Stoler MH, 2018, GYNECOL ONCOL, V149, P498, DOI 10.1016/j.ygyno.2018.04.007
  24. Thomsen LT, 2015, INT J CANCER, V137, P193, DOI 10.1002/ijc.29374
  25. Torres KL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201262
  26. Wentzensen N, 2017, INT J CANCER, V140, P2192, DOI 10.1002/ijc.30579
  27. Wright TC, 2015, GYNECOL ONCOL, V136, P189, DOI 10.1016/j.ygyno.2014.11.076
  28. Wright TC, 2011, AM J CLIN PATHOL, V136, P578, DOI 10.1309/AJCPTUS5EXAS6DKZ

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - FM/MPR
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - LIM/38
Carregar mais